Corcept is a leader in the research and development of cortisol modulators. Learn more about our work, products, and commitment to patients.
Employees: 201-500
Founded date: 1998
Investors 1
| Date | Name | Website |
| - | Longitude ... | longitudec... |
Mentions in press and media 5
| Date | Title | Description |
| 06.01.2026 | Clarivate Identifies Eleven Potential Blockbuster and Transformative Therapies in its 2026 Drugs to Watch Report | Anticipated advancements in weight loss, diabetes, oncology, rare conditions and protein degraders poised to reshape patient care LONDON, Jan. 6, 2026 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative i... |
| 31.12.2025 | Stocks making the biggest moves midday: Nike, Corcept Therapeutics, Taiwan Semiconductor & more | - |
| 08.12.2021 | Corcept Therapeutics Announces Extension of Previously Announced Tender Offer | MENLO PARK, Calif., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) (“Corcept”) a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychia... |
| 08.11.2021 | Corcept Therapeutics Incorporated announces an Equity Buyback for 10,000,000 shares, representing 8.66% for $237.5 million. | Corcept Therapeutics Incorporated (NasdaqCM:CORT) announces a share repurchase program. Under the offer, the company will repurchase up to 10,000,000 shares. The shares will be repurchased at a price not greater than $23.75 nor less than $2... |
| 11.07.2006 | The Corcept case study: Big money at Stanford & medical conflicts of interest | Alan Schatzberg Stanford University’s medical school is laden with conflicts of interest. Leading professors are producing favorable research results on medicines they will personally profit from. If you are interested in this, our Mercury ... |